NasdaqGM - Delayed Quote • USD
Corvus Pharmaceuticals, Inc. (CRVS)
At close: April 24 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.12 | -0.12 | -0.55 | -0.77 |
| Low Estimate | -0.12 | -0.12 | -0.55 | -0.77 |
| High Estimate | -0.12 | -0.12 | -0.55 | -0.77 |
| Year Ago EPS | -0.17 | -0.14 | -0.56 | -0.55 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 1 |
| Avg. Estimate | -- | -- | -- | 16.9M |
| Low Estimate | -- | -- | -- | 16.9M |
| High Estimate | -- | -- | -- | 16.9M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.16 | -0.14 | -0.12 | -0.12 |
| EPS Actual | -0.17 | -0.14 | -0.12 | -0.14 |
| Difference | -0.01 | 0 | 0 | -0.02 |
| Surprise % | -6.30% | 0.00% | 0.00% | -16.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.12 | -0.12 | -0.55 | -0.77 |
| 7 Days Ago | -0.12 | -0.12 | -0.55 | -0.77 |
| 30 Days Ago | -0.11 | -0.11 | -0.48 | -0.61 |
| 60 Days Ago | -0.11 | -0.12 | -0.49 | -0.62 |
| 90 Days Ago | -0.11 | -0.12 | -0.49 | -0.62 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CRVS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 29.40% | -- | -- | 1.50% |
| Next Qtr. | 14.30% | -- | -- | 11.40% |
| Current Year | 1.80% | -- | -- | 5.20% |
| Next Year | -40.00% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 4/1/2024 |
| Maintains | Mizuho: Neutral to Neutral | 3/27/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/20/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/7/2023 |
| Reiterates | Mizuho: Neutral to Neutral | 6/16/2023 |
| Maintains | Ladenburg Thalmann: Buy to Buy | 5/30/2023 |
Related Tickers
LPTX Leap Therapeutics, Inc.
3.2900
+2.81%
PDSB PDS Biotechnology Corporation
3.2500
+1.56%
CLSD Clearside Biomedical, Inc.
1.3400
-2.19%
EFTR eFFECTOR Therapeutics, Inc.
1.8500
-4.64%
AFMD Affimed N.V.
4.8800
-8.79%
TCON TRACON Pharmaceuticals, Inc.
1.8900
+2.16%
MREO Mereo BioPharma Group plc
2.7800
0.00%
CLRB Cellectar Biosciences, Inc.
3.0600
-1.61%
CTMX CytomX Therapeutics, Inc.
1.6300
-2.98%
XFOR X4 Pharmaceuticals, Inc.
1.2900
+4.88%